Parkinsonism Relat Disord. 2007;13 Suppl 3:S469-77.

Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point.

Bartus RT, Herzog CD, Bishop K, Ostrove JM, Tuszynski M, Kordower JH, Gasmi M.

Source

Ceregene, Inc., San Diego, CA 92121, USA.

Abstract

PURPOSE:

To develop CERE-120 (AAV-NTN) as a novel therapy for Parkinson's disease (PD) that might restore function of degenerating dopamine neurons and prevent further degeneration.

SCOPE:

A nonclinical program demonstrated that NTN expression can be predictably controlled following CERE-120 administration, provides clear evidence of efficacy in numerous animal models and is safe at dose multiples that far exceed those required for efficacy. Preliminary, open label evidence in PD subjects offers corroborative support for these observations.

CONCLUSIONS:

CERE-120 may represent an important, novel therapy for PD, though the clinical data require confirmation with additional clinical tests, including an ongoing multi-center, double-blinded controlled trial.

PMID:: 18267286; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

COS Scholar Universe

Medical

Supplemental Content

Related citations

Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. [Mol Ther. 2007]
Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease.
Gasmi M, Herzog CD, Brandon EP, Cunningham JJ, Ramirez GA, Ketchum ET, Bartus RT. Mol Ther. 2007 Jan; 15(1):62-8.
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. [Lancet Neurol. 2008]
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.
Marks WJ Jr, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, Taylor R, Cahn-Weiner DA, Stoessl AJ, Olanow CW, et al. Lancet Neurol. 2008 May; 7(5):400-8. Epub 2008 Apr 2.
Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. [Neurosurgery. 2009]
Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease.
Herzog CD, Brown L, Gammon D, Kruegel B, Lin R, Wilson A, Bolton A, Printz M, Gasmi M, Bishop KM, et al. Neurosurgery. 2009 Apr; 64(4):602-12; discussion 612-3.
Review Gene therapy of Parkinson's disease using adeno-associated virus (AAV) vectors. [J Neural Transm Suppl. 2000]
Review Gene therapy of Parkinson's disease using adeno-associated virus (AAV) vectors.
Ozawa K, Fan DS, Shen Y, Muramatsu S, Fujimoto K, Ikeguchi K, Ogawa M, Urabe M, Kume A, Nakano I. J Neural Transm Suppl. 2000; (58):181-91.
Review Gene therapy for Parkinson's disease. [J Neural Transm Suppl. 2003]
Review Gene therapy for Parkinson's disease.
Mochizuki H, Mizuno Y. J Neural Transm Suppl. 2003; (65):205-13.

See reviews... See all...

Cited by 4 PubMed Central articles

Review AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects. [Invest Ophthalmol Vis Sci. 2011]
Review AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects.
Han Z, Conley SM, Naash MI. Invest Ophthalmol Vis Sci. 2011 May; 52(6):3051-9. Epub 2011 May 10.
Review Gene therapy in Parkinson's disease: rationale and current status. [CNS Drugs. 2010]
Review Gene therapy in Parkinson's disease: rationale and current status.
Feng LR, Maguire-Zeiss KA. CNS Drugs. 2010 Mar; 24(3):177-92.
Review Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS. [Pharmacol Res. 2010]
Review Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.
Lim ST, Airavaara M, Harvey BK. Pharmacol Res. 2010 Jan; 61(1):14-26. Epub 2009 Oct 17.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Issues regarding gene therapy products for Parkinson's disease: the development ...
Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point.
Parkinsonism Relat Disord. 2007 ;13 Suppl 3:S469-77.

PubMed
Expression, bioactivity, and safety 1 year after adeno-associated viral vector t...
Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease.
Neurosurgery. 2009 Apr ;64(4):602-12; discussion 612-3.

PubMed
A review of phase III clinical trials of prostate cancer chemoprevention.
A review of phase III clinical trials of prostate cancer chemoprevention.
Ann R Coll Surg Engl. 2007 Apr ;89(3):207-11.

PubMed
MR findings of prostatic urethral polyp in an adult.
MR findings of prostatic urethral polyp in an adult.
Eur Radiol. 2003 Dec ;13 Suppl 6:L105-8. Epub 2002 Oct 24 .

PubMed
Antimuscarinics and bladder outlet obstruction: From a contraindication to an in...
Antimuscarinics and bladder outlet obstruction: From a contraindication to an indication?
Neurourol Urodyn. 2010 ;29 Suppl 1:S46-50.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: